These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7762010

  • 1. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP, Goudie J, Nishiki K, Williams PD.
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [Abstract] [Full Text] [Related]

  • 2. Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
    Jin C, Jung I, Ku HJ, Yook J, Kim DH, Kim M, Cho JH, Oh CH.
    Toxicology; 1999 Nov 05; 138(2):59-67. PubMed ID: 10576583
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A, Eggimann P, Pagani JL, Revelly JP, Decosterd LA, Marchetti O, Pannatier A, Voirol P, Que YA.
    Burns; 2015 Aug 05; 41(5):956-68. PubMed ID: 25678084
    [Abstract] [Full Text] [Related]

  • 7. [Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].
    Yagi Y, Nawa T, Kurata Y, Shibasaki S, Suzuki H, Kurosawa T.
    Jpn J Antibiot; 2009 Jun 05; 62(3):241-52. PubMed ID: 19882983
    [Abstract] [Full Text] [Related]

  • 8. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T, Pooyeh S, Hannemann J, Baumann J, Tauber R, Baumann K.
    Int J Clin Pharmacol Ther; 1999 Oct 05; 37(10):475-86. PubMed ID: 10543314
    [Abstract] [Full Text] [Related]

  • 9. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.
    Pharmacotherapy; 2009 Aug 05; 29(8):914-23. PubMed ID: 19637944
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS.
    Diagn Microbiol Infect Dis; 2010 Nov 05; 68(3):251-8. PubMed ID: 20851549
    [Abstract] [Full Text] [Related]

  • 11. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain.
    Sunagawa M, Matsumura H, Sumita Y, Nouda H.
    J Antibiot (Tokyo); 1995 May 05; 48(5):408-16. PubMed ID: 7797443
    [Abstract] [Full Text] [Related]

  • 12. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A, Japan Febrile Neutropenia Study Group.
    J Infect Chemother; 2015 Jan 05; 21(1):16-22. PubMed ID: 25239059
    [Abstract] [Full Text] [Related]

  • 13. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ.
    J Antimicrob Chemother; 1995 Jul 05; 36 Suppl A():191-205. PubMed ID: 8543495
    [Abstract] [Full Text] [Related]

  • 14. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA.
    J Antimicrob Chemother; 2014 Aug 05; 69(8):2043-55. PubMed ID: 24744302
    [Abstract] [Full Text] [Related]

  • 15. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL, Smith JW, Geckler RW, Wilson SE.
    South Med J; 1995 Apr 05; 88(4):397-404. PubMed ID: 7716590
    [Abstract] [Full Text] [Related]

  • 16. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR.
    Drug Saf; 2000 Mar 05; 22(3):191-4. PubMed ID: 10738843
    [Abstract] [Full Text] [Related]

  • 17. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP, Herring AH, Benjamin DK, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB, Best Pharmaceuticals for Children Act-Pediatric Trials Network.
    Pediatr Infect Dis J; 2013 Jul 05; 32(7):748-53. PubMed ID: 23838776
    [Abstract] [Full Text] [Related]

  • 18. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.
    Surg Infect (Larchmt); 2005 Jul 05; 6(3):269-82. PubMed ID: 16201937
    [Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Tang HJ, Chuang YC, Ko WC, Chen CC, Shieh JM, Chen CH, Lee NY, Chiang SR.
    Int J Infect Dis; 2012 Jan 05; 16(1):e34-40. PubMed ID: 22088863
    [Abstract] [Full Text] [Related]

  • 20. Neurotoxicity of carbapenem antibacterials.
    Norrby SR.
    Drug Saf; 1996 Aug 05; 15(2):87-90. PubMed ID: 8884160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.